Following is a summary of current health news briefs.
U.S. proposes scrapping some obsolete Medicare regulations 2013-02-05T010951Z_2_BRE914024_RTROPTC_0_US-USA-HEALTHCARE-HOSP ITALS.XML () -
Merck hit with $285,000 verdict in Fosamax trial
NEW YORK (Reuters) - A federal jury on Tuesday ordered Merck & Co Inc <MRK.N> to pay $285,000 in a lawsuit over the risks of its osteoporosis drug Fosamax, the second loss for the company after several earlier trials. The eight-person jury in U.S. District Court in Manhattan found that Merck failed to warn plaintiff Rhoda Scheinberg's doctors of the risks associated with Fosamax. The jury rejected the plaintiff's argument that Fosamax was a defective product.
Massachusetts cites violations at 32 compounding pharmacies 2013-02-05T195957Z_1_BRE91414K_RTROPTC_0_US-MENINGITIS-PHARMACI ES-VIOLATIONS.XML () -
U.S. Army to build soldier "resilience" to fight suicides, violence
TACOMA, Washington (Reuters) - The U.S. Army, grappling with a spike in military suicides, plans to take steps to improve soldiers' resilience to mental health problems to combat such deaths as well as depression, substance abuse, and violent behavior, Army Secretary John McHugh said on Monday. McHugh ordered Army officials to lay out detailed plans by February 15 to boost soldiers' "physical, emotional and psychological resilience," but did not reveal program specifics, such as estimated costs or goals.
FDA approves generic version of cancer drug Doxil 2013-02-04T190948Z_1_BRE9130U6_RTROPTC_0_US-CANCER-DRUG-APPROVA L.XML () -
GSK promises to publish detailed drug trial data
LONDON (Reuters) - British drugmaker GlaxoSmithKline <GSK.L>, which paid $3 billion last year to settle charges that it gave misleading information on its medicines, said on Tuesday it would publish more of its clinical research data. When the company agreed to the fines last July, government officials called it the largest healthcare fraud case in U.S. history, involving Glaxo drugs such as the antidepressant Paxil and diabetes pill Avandia.
Galapagos says GSK starting trials of its new drug
BRUSSELS (Reuters) - Belgian biotech company Galapagos <GLPG.BR> said on Tuesday that its partner GlaxoSmithKline (GSK) <GSK.L> planned to start Phase II studies into a drug candidate to treat two auto-immune disorders. Galapagos said in a statement that GSK would launch the studies for compound GSK2586184 in systemic lupus erythematosus (SLE) and chronic plaque psoriasis.
Centene profit falls 70 percent on high flu costs 2013-02-05T200126Z_2_BRE91414E_RTROPTC_0_US-CENTENE-RESULTS.XML () -
Sanofi says Zaltrap approved in Europe for bowel cancer
PARIS (Reuters) - French drugmaker Sanofi <SASY.PA> said on Tuesday that its Zaltrap drug had been approved for marketing in the European Union to treat advanced bowel cancer. The approval follows a recommendation from the European Medicines Agency in November based on a late-stage study of the drug that showed significant improvement in survival among patients with colon cancer.
Bayer to partner on reversing bleeding from Xarelto
FRANKFURT (Reuters) - German drugmaker Bayer <BAYGn.DE> said on Tuesday it planned to collaborate with U.S. peer Portola Pharmaceuticals to study several drugs that reverse the effects of its blood-thinner Xarelto. Bayer said it expected to complete the study in the second half of this year.